Stock SPAG SPAGO NANOMEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Spago Nanomedical AB

Equities

SPAG

SE0004899474

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 10:42:26 2024-04-26 am EDT 		5-day change 1st Jan Change
0.36 SEK +0.56% Intraday chart for Spago Nanomedical AB +8.76% +10.09%
Apr. 24 Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad CI
Apr. 16 Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 185.6 315.4 270 197.7 57.29 80.9 80.9 -
Enterprise Value (EV) 1 169.1 303.3 270 197.7 -4.806 26.16 26.9 24.9
P/E ratio -15.6 x -14.9 x -12.2 x -4.85 x - -0.76 x -3.6 x -1.8 x
Yield - - - - - - - -
Capitalization / Revenue - 10,515 x 790 x 300 x 54.4 x 59.3 x 2.83 x 5.66 x
EV / Revenue - 10,110 x 790 x 300 x -4.56 x 21.7 x 0.94 x 1.74 x
EV / EBITDA -15.8 x -15.3 x -14.5 x -5.09 x 0.12 x -0.61 x -0.8 x -0.49 x
EV / FCF -4.62 x -14.2 x -13.9 x -5.5 x 0.13 x -0.58 x -0.84 x -0.48 x
FCF Yield -21.6% -7.03% -7.18% -18.2% 794% -172% -119% -207%
Price to Book 1.52 x 2.29 x 1.69 x 1.07 x - 1.72 x 1.8 x 1.8 x
Nbr of stocks (in thousands) 16,716 21,030 31,545 41,182 90,944 224,715 224,715 -
Reference price 2 11.10 15.00 8.560 4.800 0.6300 0.3600 0.3600 0.3600
Announcement Date 1/30/19 1/30/20 2/2/21 2/2/22 2/2/23 2/7/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 - 0.03 0.342 0.66 1.054 1.203 28.6 14.3
EBITDA 1 -10.72 -19.85 -18.6 -38.82 -39.11 -42.79 -33.5 -51.1
EBIT 1 -11.09 -20.21 -18.96 -39.19 -39.46 -43.07 -34.15 -51.25
Operating Margin - -67,370% -5,544.44% -5,938.18% -3,744.31% -3,580.47% -119.41% -358.39%
Earnings before Tax (EBT) 1 -11.09 -20.21 -18.93 -39.07 - -42.22 -14.9 -35.5
Net income 1 -11.09 -20.21 -18.93 -39.07 - -42.22 -14.9 -35.5
Net margin - -67,370% -5,534.5% -5,919.85% - -3,509.81% -52.1% -248.25%
EPS 2 -0.7100 -1.010 -0.7000 -0.9900 - -0.4300 -0.1000 -0.2000
Free Cash Flow 1 -36.6 -21.34 -19.38 -35.94 -38.19 -45.06 -32 -51.5
FCF margin - -71,116.67% -5,666.08% -5,445.76% -3,623.06% -3,745.8% -111.89% -360.14%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 1/30/19 1/30/20 2/2/21 2/2/22 2/2/23 2/7/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q2 2023 Q3 2023 Q4
Net sales - - -
EBITDA - - -
EBIT 1 - -7.308 -9.586
Operating Margin - - -
Earnings before Tax (EBT) - - -
Net income 1 -7.866 -7.113 -9.417
Net margin - - -
EPS -0.0900 - -
Dividend per Share - - -
Announcement Date 7/31/23 11/3/23 2/7/24
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - - -
Net Cash position 1 16.5 12.1 - - 62.1 45.2 54 56
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -36.6 -21.3 -19.4 -35.9 -38.2 -45.1 -32 -51.5
ROE (net income / shareholders' equity) -9.65% -15.6% -12.7% - -20.5% -35.4% -34% -77%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 7.310 6.540 5.060 4.490 - 0.1900 0.2000 0.2000
Cash Flow per Share -0.6800 -1.060 - - - - - -
Capex 1 - - - - - 7 1 1
Capex / Sales - - - - - 700% 3.5% 6.99%
Announcement Date 1/30/19 1/30/20 2/2/21 2/2/22 2/2/23 2/7/24 - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Spago Nanomedical AB

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

1st Jan change Capi.
SPAGO NANOMEDICAL AB Stock Spago Nanomedical AB
+10.09% 7.38M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-20.45% 10.82B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+43.17% 3.25B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-35.86% 2.11B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-17.21% 2.08B
VERACYTE, INC. Stock Veracyte, Inc.
-29.81% 1.48B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.56% 1.02B
SEEGENE, INC. Stock Seegene, Inc.
-4.37% 733M
CAREDX, INC Stock CareDx, Inc
-37.00% 391M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 377M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. SPAG Stock
  4. Financials Spago Nanomedical AB